Persistence of interleukin (IL)-17A+ T lymphocytes and IL-17A expression in treatment-resistant psoriatic plaques despite ustekinumab therapy

Br J Dermatol. 2017 Jul;177(1):267-270. doi: 10.1111/bjd.15029. Epub 2017 Jun 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Dermatologic Agents / therapeutic use*
  • Humans
  • Interferon-gamma / metabolism
  • Interleukin-17 / metabolism*
  • Interleukins / metabolism
  • Psoriasis / drug therapy*
  • Psoriasis / immunology
  • RNA, Messenger / metabolism
  • Receptors, Interleukin / metabolism
  • Skin / immunology
  • Th17 Cells / immunology*
  • Tumor Necrosis Factor-alpha / metabolism
  • Ustekinumab / therapeutic use*

Substances

  • Dermatologic Agents
  • IL17A protein, human
  • Interleukin-17
  • Interleukins
  • RNA, Messenger
  • Receptors, Interleukin
  • Tumor Necrosis Factor-alpha
  • interleukin-22 receptor
  • Interferon-gamma
  • Ustekinumab
  • interleukin-22